Adlai Nortye announces first dose and FDA IND clearance for AN4035
Adlai Nortye said it dosed its first patient in Australia and received U.S. FDA IND clearance for AN4035, a pan-RAS(ON) inhibitor-based ADC.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.